Travere Therapeutics TVTX underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 4 | 1 | 0 | 0 |
| Last 30D | 3 | 0 | 0 | 0 | 0 |
| 1M Ago | 5 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.79, with a high estimate of $25.00 and a low estimate of $12.00. This current average reflects an increase of 11.37% from the previous average price target of $17.77.
Interpreting Analyst Ratings: A Closer Look
The standing of Travere Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vamil Divan | Guggenheim | Lowers | Buy | $23.00 | $25.00 |
| Greg Harrison | B of A Securities | Lowers | Buy | $18.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Lowers | Buy | $18.00 | $23.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $23.00 | $20.00 |
| Edward Nash | Canaccord Genuity | Raises | Buy | $23.00 | $18.00 |
| Vamil Divan | Guggenheim | Announces | Buy | $25.00 | - |
| Carly Kenselaar | Citigroup | Raises | Buy | $23.00 | $14.00 |
| Greg Harrison | B of A Securities | Raises | Buy | $19.00 | $18.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $23.00 | $20.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $20.00 | $19.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $20.00 | $19.00 |
| Carter Gould | Barclays | Raises | Overweight | $14.00 | $12.00 |
| Allison Bratzel | Piper Sandler | Raises | Neutral | $12.00 | $11.00 |
| Laura Chico | Wedbush | Raises | Outperform | $16.00 | $13.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travere Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Travere Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Travere Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Travere Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Travere Therapeutics Better
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Breaking Down Travere Therapeutics's Financial Performance
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Travere Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 68.08% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Travere Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -130.11% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Travere Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -157.84%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Travere Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.59%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Travere Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 26.62. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
